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Abstract
Background
Mass drug administration (MDA) treatment of active trachoma with antibiotic is recom-
mended to be initiated in any district where the prevalence of trachoma inflammation,
follicular (TF) is 10% in children aged 1–9 years, and then to continue for at least three
annual rounds before resurvey. In The Gambia the PRET study found that discontinuing
MDA based on testing a sample of children for ocular Chlamydia trachomatis(Ct) infec-
tion after one MDA round had similar effects to continuing MDA for three rounds. More-
over, one round of MDA reduced disease below the 5% TF threshold. We compared the
costs of examining a sample of children for TF, and of testing them for Ct, with those of
MDA rounds.
Methods
The implementation unit in PRET The Gambia was a census enumeration area (EA) of
600–800 people. Personnel, fuel, equipment, consumables, data entry and supervision
costs were collected for census and treatment of a sample of EAs and for the examination,
sampling and testing for Ct infection of 100 individuals within them. Programme costs and
resource savings from testing and treatment strategies were inferred for the 102 EAs in the
study area, and compared.
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Results
Census costs were $103.24 per EA plus initial costs of $108.79. MDA with donated azithro-
mycin cost $227.23 per EA. The mean cost of examining and testing 100 children was
$796.90 per EA, with Ct testing kits costing $4.80 per result. A strategy of testing each EA
for infection is more expensive than two annual rounds of MDA unless the kit cost is less
than $1.38 per result. However stopping or deciding not to initiate treatment in the study
area based on testing a sample of EAs for Ct infection (or examining children in a sample of
EAs) creates savings relative to further unnecessary treatments.
Conclusion
Resources may be saved by using tests for chlamydial infection or clinical examination to
determine that initial or subsequent rounds of MDA for trachoma are unnecessary.
Author Summary
Trachoma, caused by infection with a bacterium (chlamydia) is controlled by mass drug
administration (MDA), which is recommended yearly for districts in which a trachoma
problem has been found to exist. The decision, after several rounds, that MDA is no longer
needed is currently based on clinical signs of trachoma, but these are an unreliable indica-
tor of infection. The PRET study, in the Gambia, found that tests for infection could be
used to show that subsequent rounds of MDA were redundant. This paper shows, by esti-
mating the costs, that testing children in a sample of census districts for infection can save
resources compared to (unnecessary) rounds of MDA.
Introduction
Trachoma, caused by ocular infection with Chlamydia trachomatis (Ct), is the leading infec-
tious cause of blindness worldwide and is estimated to cause 3.6% of the world’s blindness [1].
The presence of follicles and inflammation in the upper tarsal conjunctiva, known as active tra-
choma, is characteristic of childhood infection. Following years of repeated infection, the
upper tarsal conjunctiva may become so severely scarred that the eyelashes turn inwards, rub
on the eyeball and cause corneal opacity and blindness.
The World Health Organization (WHO) estimates that worldwide, 40.6 million people have
active trachoma, 8.2 million people have in turned eyelashes (trichiasis), and 1.3 million are
blind as a result of trachoma [1,2]. It was estimated in 1995 that $2.9 billion is lost in annual
revenue as a result of the loss of vision arising from trachoma[3]. Trachoma is most prevalent
in poor, rural communities with low standards of hygiene and sanitation. It is thought to be en-
demic in 57 countries [2].
The WHO recommendations for the control and elimination of trachoma are based on a
strategy with the acronym “SAFE”: Surgery for in turned eyelashes, Antibiotics to treat ocular
Ct infection, Facial cleanliness and Environmental improvement to reduce transmission of the
infection. The WHO recommends that mass treatment with an antibiotic such as azithromycin
should be given annually to districts or communities where the prevalence of follicular tracho-
ma (TF) is10% in children aged 1–9 years, continuing for at least three rounds before the
need to re-survey. In some settings however, including the Jareng village cluster in The Gambia
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[4] and Rombo district in Tanzania [5], a single round of high coverage mass azithromycin re-
duced Ct infection to very low and unsustainable levels, although the prevalence of TF would
still have indicated that intervention was needed. Testing for Ct demonstrated that further
treatments were unnecessary.
In 2007, The Gambia implemented a national plan for trachoma control [6] with a donation
of azithromycin through the International Trachoma Initiative. In this plan, based on a 2006
survey [7], extrapolation and local knowledge, 11 districts demonstrated or believed by the pro-
gramme to have a prevalence of TF greater than 10% in 1–9 year olds were assigned to mass
drug administration (MDA) with azithromycin. The Partnership for the Rapid Elimination of
Trachoma (PRET) study [8,9] aimed, inter alia, to test whether one round of MDA would be
sufficient to control active trachoma across a wide geographical area, comprising four of the
eleven districts assigned to MDA and containing 67,156 people. The study compared commu-
nities randomised to receive yearly MDA for three years or to a stopping rule (SR) in which
mass treatment would cease if the estimated prevalence of either TF or Ct infection at six
months were sufficiently low. A further stopping rule was applied at the district level, according
to which treatment in non-study communities would also cease if the district prevalence of in-
fection or of TF were sufficiently low,. In the study, the TF prevalence in 0–5 year-olds in the
study area was reduced below 3% after one round of treatment and Ct infection, which was at a
low level initially, was not detectable in any child at 12 and 18 months of follow up. The study
found no difference in outcome (TF or Ct infection at 36 months) between the stopping rule
communities and those in which treatment continued [8], illustrating that tests for Ct infection
(or clinical examination for TF) could be used to demonstrate that initial or subsequent rounds
of MDA were redundant.
Data were gathered during PRET The Gambia with the aim of comparing the programme
costs of implementing a stopping rule based on tests for infection with those of further rounds
of treatment and to explore the situations in which testing for infection would have a cost ad-
vantage over two further treatments. We report on these cost data and on their application to
this and other possible testing and treating strategies.
Methods
PRET study
The study was conducted from 2008 to 2011 in the Foni Bintang and Foni Kansala districts in
Western Region, and in Central Baddibu and Lower Baddibu in North Bank Region. These are
shown on the map (Fig 1). For census purposes, The Gambia is divided into geographically de-
fined census Enumeration Areas (EAs), of similar population size, notionally containing 600–
800 people. An EA is a useful unit for representative sampling, as randomly choosing EAs is
equivalent to sampling settlements with probability proportional to their size. EA geography
varies in ways which might influence costs; an EA is either a segment of a large settlement (seg-
ment) a single medium-sized settlement (single), or made up of multiple adjacent small settle-
ments (multiple).
Randomisation
The randomisation scheme in PRET has been described previously [8,9]. Briefly, all 102 EAs
were randomly assigned to one of four arms: 1) standard treatment coverage, SR; 2) standard
treatment coverage, 3 annual MDAs; 3) enhanced treatment coverage, SR; 4) enhanced treat-
ment coverage, 3 annual MDAs; under the restriction that each settlement was treated in the
same way (all EAs representing segments of the same settlement were in the same arm). The
outcomes were assessed in a random selection of 48 EAs for sampling, which was made such
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that 12 EAs per arm and per district were selected (3 EAs per arm per district) and such that
each large settlement was represented by only one of its segment EAs. This ‘sample’ of 12 EAs
per district then served as the basis for implementing district-level stopping rules in those EAs
in the district not included in the sampling.
Field and laboratory work
Details of PRET in The Gambia have been described elsewhere [8–10]. Briefly, all members of
every household in the 48 EAs selected for sampling were listed in a census and a random sam-
ple of 100 children aged 0–5 years per EA had both eyes examined for the clinical signs of tra-
choma using the WHO simplified grading system [11]. An ocular swab was then taken for
detection of ocular Ct infection by Amplicor Polymerase Chain Reaction (PCR) (Roche Molec-
ular Systems, Branchburg, NJ, USA), as previously described [12]. A new random sample of
100 children aged 0–5 was examined in each EA at 6, 12, 18, 24, 30 and 36 month follow-up
time points.
Samples were processed by two laboratory technicians at Medical Research Council (MRC)
Laboratories, The Gambia, by Amplicor PCR. The manufacturer’s instructions were followed,
except for sample preparation where a previously published method was used [12], and the ex-
tracts of five swabs were pooled, with individual testing of any positive pools.
MDA in PRET
At baseline, all 102 EAs in the four districts were mass treated with azithromycin by the Gam-
bian National Eye Health Programme (NEHP). EAs assigned to standard treatment coverage
were visited on a single day, whereas those assigned to enhanced coverage were visited a second
day to treat those not treated on the first visit. The treatment teams were kept unaware, on
their first visit to an EA, of the coverage assignments. Children were dosed using height sticks,
with cut-offs optimally derived from local height/weight data to minimise the risk of over- and
under-dosing [6,13]. EAs were usually treated by a team of six people, working in three pairs,
plus a driver. In segment EAs, all six team members worked together whereas in multiple EAs
pairs would work on their own in the different settlements. In each pair, one measured the
height and distributed the treatment, while the other recorded the treatment information
against the census in the treatment book.
Stopping rule in PRET
Under the stopping rule, the decision to treat at 12 months post-baseline was based on the clin-
ical examination and ocular Ct infection data at 6 months (Table 1). MDA was discontinued
in study EAs in the SR arms if there were either no cases of Ct infection or no cases of TF in the
Fig 1. Map of The Gambia showing location of the study area and 4 study districts.
doi:10.1371/journal.pntd.0003670.g001
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100 sampled individuals (equivalent to 95% confidence that the true prevalence was less than
5%). Furthermore, MDA was discontinued throughout a district (excluding those EAs rando-
mised to three annual treatments) if, based on the EAs that were sampled, there was 95% confi-
dence that the prevalence of infection, (or of TF) in the district was below 5%.
Cost data collection
Cost data, which included personnel, fuel, equipment, consumables, data entry and supervi-
sion, were collected for census, sampling and examination. Treatment cost data were collected
12 months post baseline from the 12 EAs assigned to the enhanced coverage treatment arm,
with the costs for one day of treatment (standard coverage) inferred by removing the costs of
the second day from the total EA treatment cost. Examination cost data were collected from
these same EAs at 18 months post baseline. Efforts were made to identify and exclude the costs
of concurrent research activity, such as personnel and consumables involved in taking eyelid
photographs, and completing consent forms.
As is recommended for cost studies [14], worksheets detailing all costs involved for the
day’s activities(examination or treatment) were completed each day. Unit costs were obtained
from local sources when available, and when not, the original source price was taken. The labo-
ratory cost of processing the samples was calculated using information provided by the MRC
Laboratories, The Gambia. Costs were obtained in US Dollars ($), British Pounds (GBP), and
Gambian Dalasi (GMD). GMD and GBP costs were converted to $ using a historic currency
conversion of an average of 366 days from the 1st January 2009 to the 1st January 2010 (http://
www.oanda.com/currency/historical-rates/). For this time period, 1GMD = $0.0377, and 1GBP
= $1.5665. Cost data were entered and analysed in Microsoft Excel 2007.
Personnel
Salaries, including overheads, were converted to a daily rate. For the census, it was assumed
that NEHP staff would first attend a training workshop, and that subsequently one census
taker, using a motorcycle, could census one EA/day. For the treatment team, per diems to
cover food and accommodation in the field were given as a single payment based on the ex-
pected number of days needed to complete the treatment. The team’s total per diem was divid-
ed by the number of days worked to obtain a daily rate. The PRET field team contained
research workers and NEHP Community Ophthalmic nurses (CONs). For costing we assumed
that three NEHP CONs (for form filling, grading and the field lab) and a NEHP driver would
undertake the work. Examination team received per diems for each day worked. Volunteers
from the communities who facilitated field work were also compensated for their time and
Table 1. Prevalence of TF and ocularC. trachomatis infection in PRET by allocation.
3 annual MDAs Stopping rule (MDA at
baseline only)
Standard coverage
(one treatment visit)
Enhanced coverage
(extra treatment visit)
Time point TF (%) Ct (%) TF (%) Ct (%) TF (%) Ct (%) TF (%) Ct (%)
Baseline 6.5 0.8 6.1 0.6 5.8 0.4 6.8 1.1
6 months 2.4 0.1 2.4 0 2.2 0 2.5 0.1
12 months 2.6 0 2.7 0 2.6 0 2.7 0
18 months 1.6 0 1.7 0 1.9 0 1.4 0
24 months 2.3 0 2.1 0.1 2.4 0.04 2.1 0.04
30 months 2.4 0.4 3.6 0.1 2.8 0.2 3.2 0.3
36 months 2.6 0.6 2.9 0.4 2.4 0.6 3.1 0.4
doi:10.1371/journal.pntd.0003670.t001
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effort. For the laboratory, personnel costs included the salaries of two lab technicians, em-
ployed locally by the MRC Laboratories, who spent 85% of their time processing the samples.
Based on an average of 920 samples being processed a week, a lab personnel cost per sample
processed was calculated.
Fuel
The cost of fuel was calculated based on the distances in kilometres (km) travelled by the teams
as read from the vehicle dashboards and the refuelling costs.
Equipment
Equipment for the treatment team included the vehicle, height sticks and weighing scales.
Equipment for the examination team included the vehicle, table, chairs and loupes. Laboratory
costs were obtained for all equipment necessary to run Amplicor PCR. The equipment cost/
day was calculated by dividing the capital cost, by the equipment’s life expectancy in years mul-
tiplied by 345 (number of assumed working days per year).
Consumables
For the census, consumable costs of clipboards, pens, phone credit and stationery were includ-
ed. For treatment, consumables included the cost of medication. Azithromycin for trachoma
control is donated free to the NEHP and to other trachoma control programmes by the Inter-
national Trachoma Initiative, but storage and transport costs are met by the programmes and
were included. The costing gold standard [14] of taking into account the opportunity cost (i.e.
when goods or services are donated, a ‘replacement’ cost is imputed) was applied (drugs were
assumed purchased rather than donated). In this case we assumed the online market rates of
$20 for 30x250mg azithromycin tablets, and $9 for a bottle of 30 ml paediatric oral suspension.
Costs of tetracycline eye ointment, which is purchased and offered to children aged under 6
months and pregnant women in MDA campaigns were included. For examination, field con-
sumables included swabs, tubes, labels, paper, gloves, waste bags, ointment, torches and batter-
ies, phone credit and stationery. For the laboratory, costs of all consumables necessary for
processing samples by Amplicor were included, together with the cost of kits.
Test kit costs
We define the Amplicor test ‘kit cost’ as the amount spent on Amplicor kits to generate one
test result using a strategy of testing in pools of five and retesting all positive or equivocal pools.
Data entry
We assumed the NEHP would enter data rather than using the PRET research data entry sys-
tem. We assumed that one data entry clerk would be employed, entering two EAs per day for
treatment data, and four EAs per day for examination data.
Supervision
We assumed that the NEHP manager (a senior civil servant) would spend one day per week su-
pervising the census, and two days per week in the field to supervise the treatment and exami-
nation teams (one day per team). Supervision costs included the manager’s salary, vehicle (car
depreciation) and fuel, calculated as outlined above. For the laboratory, we assumed that locally
employed technicians were supervised by a Scientific Officer (a scientist with a Master’s degree
employed by the MRC on a sub-regional salary scale) at 5% of their time.
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Cost calculations
The treatment and exam cost data were recorded from twelve EAs (five multiple, two single
and five segments) at the 12 and 18 month time points respectively. Census costs were estimat-
ed from records of training workshops and field records at baseline. Total EA level costs were
calculated by summing the personnel, fuel, equipment, consumables, data entry and supervi-
sion costs. For both examination and treatment, when more than one EA was visited in a day,
the number of individuals treated, or number of children examined, in the EA was used to pro-
vide a weighted cost per EA for items that were not “per individual/child” (personnel, fuel, and
equipment costs). Summary estimates were made for each type of EA and then extrapolated
for the study sample (48 EAs), and for the whole study area (102 EAs), according to their de-
composition by EA type. Results are expressed as total costs in US dollars ($) over the study
area, costs per EA and costs per head of the population of the study area.
Ethical approval
The study was conducted in accordance with the declaration of Helsinki. Written informed
consent was given by adult subjects or by the parent or guardian of child participants. Ethical
approval was obtained from the London School of Hygiene & Tropical Medicine (LSHTM),
UK, Ethics Committee and The Gambia Government/Medical Research Council (MRC) joint
Ethics Committee, The Gambia.
Results
PRET study[8]
Fig 2 illustrates the target populations, randomisations, study arms, MDA treatment rounds
and effects of the stopping rules (based on examining and testing 100 children per sampled EA
6 months after the first MDA round in the PRET study. The mean and median baseline EA
populations in the 48 sampled EAs were 701 and 667 respectively. The mean and median base-
line EA populations in the study area of 102 EAs were 658 and 622 respectively. The baseline
TF prevalence was 6.5% of 0–5 year olds. Six months after the baseline mass treatment, TF
prevalence was 2.4% (95% CI 1.6–3.1) and no Ct infection was found in any of the 24 EAs ran-
domised to the stopping rule. Implementing the stopping rule led to mass treatments being dis-
continued in these 24 EAs. Furthermore, implementing the district stopping rule led to
treatment being discontinued in all 54 non-study EAs across all four districts. MDA only con-
tinued in the 24 EAs randomised to three annual treatments, where MDA at 12 months and 24
months was implemented regardless of the prevalence of TF or of infection. At baseline, the
prevalence of Ct infection was 0.8% (95% CI 0.3–1.2). On average, enhancing coverage by mak-
ing an extra visit improved MDA coverage of 0–9 year-olds by 3%(from 90.2% to 93.2%).[8] At
36 months there were no differences in the study outcomes between the study arms (Table 1).
Specifically, neither enhanced coverage nor the two additional mass treatments in the 3x annu-
al treatment arm had any effect on TF or infection prevalence at 36 months. There were also
no differences at intermediate time-points. Thus, a single round of MDA reduced TF to low
levels, and there were no apparent benefits to two further rounds of mass treatment, relative to
discontinuing MDA post-baseline based on tests for infection[8].
Alternative sampling scenario calculations
In PRET 48 EAs were sampled and 100 children 0–5 per EA examined and tested for infection
at each time point. This was because the PRET study explored a stopping rule in each EA,
necessitating almost all the eligible children aged 0–5 being examined in order to have 95%
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confidence(with zero observed cases) that the underlying prevalence of TF or of Ct infection in
the EA was less than 5%. For a stopping rule applied to the whole study area a smaller number
of sampled EAs would have sufficed for 95% confidence that the underlying area-wide preva-
lence of TF or Ct infection were less than 5%. We used recommendations for sampling surveys
in the WHOmanual for trachoma programme managers [15] to estimate the number of EAs
that would have been needed to be sampled, examined and/or tested in order to determine a
stopping rule of 95% confidence TF or Ct infection prevalence less than 5% across the study
area of 102 EAs, given the prevalences observed in the PRET sample. These calculations were
based on the design effects [16] estimated in EA summarised data from PRET at baseline and 6
months [8].
Costs
Costs are presented per EA and then applied as estimates to the study area of 102 EAs and
67,156 people according to decomposition by EA type as outlined above and in Tables 2,3,and 4.
Census costs
The breakdown of census costs is shown in Table 2. The cost of the census was $108.79 for
training plus $103.24 per EA. The estimated cost of census in the study area was $10,639.27.
Per diem costs were the greatest component of training, and supervision costs the greatest com-
ponent of the census.
Fig 2. Summary of PRET study illustrating randomisations, target populations and effects of stopping rules based on examination and testing
after one MDA round.
doi:10.1371/journal.pntd.0003670.g002
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Table 2. Census costs by item.
Item Cost
(USD)
Training (ﬁxed):
Daily salary of CON for 2 days 11.63
Daily salary of NECP manager for 2 days 74.545
Per diem of CON for 2 days (assume CON displaced from home) 22.62
Total training cost 108.79
Cost per EA:
Personnel
CON monthly salary Multiplied by 1.2 for overheads and divided by 22 for daily salary 5.71
CON per diem (assume CON not displaced from home) 7.54
Materials
Stationery (Pens & Clipboard: 1/census taker) 1.89
Paper (average number of households per EA: 65; average number of people in EA: 712; therefore average number of people per
household: 11, which could ﬁt onto one piece of paper): 65 sheets per EA)
0.50
Plastic wallet (1/EA) 0.56
Phone credit (D50/week) 0.38
Transport
Motorcycle depreciation (€1,735 cost + (£2,050 freight charges + £230 insurance for shipment of 7 bikes)). Life expectancy = 5 years Cost/
day = cost of motorbike / (345 x life expectancy)
1.52
Fuel (D32/litre, assume 20km /litre). EA fuel cost = number of km x 32 / 20. Average number of km = 71.8km (based one just one visit to
each EA)
4.33
Data entry (2 EAs/day, 1 NECP enterer) Average cost per EA of data entry = 0.5*(salary * 1.2 (overheads) /22) 3.08
Supervision
Salary (Salary of NECP manager for 1 day/week, divide by 22) 37.37
Vehicle depreciation (Depreciation cost of vehicle: $49,900 + D23,000 insurance, licence & road tax. 16.84
49,900/(345x10) = $14.464 = cost/day of vehicle
D23,000 x 0.0377 = $867.1
$867.1 / 365 = $2.376/day of tax, licence etc.
$2.376 + $14.464 = total cost of vehicle per day
Fuel (to go to ﬁeld one day/week): Average distance travelled to go into ﬁeld for one day = 195km from Banjul to Farafenni. 23.52
Total per EA cost 103.24
Cost for 102 EAs 10,530.48
Total census cost for study area 10,639.27
Assumptions:
• Costs were obtained in US Dollars (USD), British Pounds (GBP), and Gambian Dalasi (GMD). GMD and GBP costs were converted to USD using a
historic currency conversion of an average of 366 days from the 01st January 2009 to the 1st of January 2010 (http://www.oanda.com/currency/
historical-rates/). For this time period, 1GMD = 0.0377 USD, and 1GBP = 1.5665 USD.
• For training, the following assumptions were made:
• Two days’ training.
• Training was done at the Regional Eye Care Centre, so there are no facility costs.
• Training was done by the manager of the NECP, who has no per diem.
• For census taking, the following assumptions were made:
• One NECP census takers on a motorcycle per EA
• One census taker can census 1 EA/day (based on PRET)
• The census taker would not do a ﬁrst separate trip to make a household head list
doi:10.1371/journal.pntd.0003670.t002
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Treatment costs
Over the study area the estimated average cost of one MDA round in an EA was $227.73 for
standard treatment and $296.05 for enhanced treatment (Table 3). The estimated cost of a
standard round of MDA in the study area(102 EAs) was $23,228.46, or $0.35 per head of target
population, increasing to $0.39 per head for the extra visit in the enhanced treatment. Person-
nel represented the greatest treatment cost, followed by supervision (Fig 3). Treatment costs
varied slightly depending on the geography of the EA, with single EAs being cheapest to treat
and segments the most expensive (data in Table 2).
Table 3. Costs of MDA rounds.
EAs made up of
smaller settlements
(M-multiple)
EAs made up of one
settlement (S-single)
EAs part of a large
settlement (G-
segment)
Weighted average
across 48 study EAs:
25M 7S 16G
Weighted average
across 102 EAs in
the study area: 31M
11S 60G
Costing category Standard Enhanced Standard Enhanced Standard Enhanced Standard Enhanced Standard Enhanced
Personnel 109.4 168.3 94.7 106.4 136.4 204.3 116.26 171.27 123.70 182.80
Fuel 6.3 10.2 3.7 4.1 12 15.7 7.82 11.14 9.37 12.78
Equipment 9.3 14.8 8.3 9.3 10.5 15.8 9.55 14.33 9.90 14.80
Supervision 77.8 77.8 77.8 77.8 77.8 77.8 77.8 77.8 77.8 77.8
Data entry 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
Tetracycline 2.8 3.5 1.7 2.2 4.8 5.9 3.31 4.11 2.98 4.77
Average total cost/EA,
excluding azithromycin
208.7 277.7 189.3 202.9 244.6 322.6 217.84 281.76 227.73 296.05
Azithromycin 1658.6 1874.3 945.5 1195.1 1088.6 1192.9 1364.61 1548.12 1246.40 1400.23
Average total cost/EA,
including azithromycin
1867.3 2152 1134.8 1398 1333.2 1515.5 1582.44 1829.88 1474.13 1696.27
doi:10.1371/journal.pntd.0003670.t003
Table 4. Estimated examination and testing cost per EA in the study EAs and across the study area, by costing category (USD).
Costing category Average cost per EA (USD)
EA type: Multiple
(M)
Single
(S)
Segment
(G)
48 study sample EAs adjusted for
EA type(16M 7S 25G)
102 study area EAs adjusted for EA
type(31M 11S 60G)
Field personnel 58 121.9 78.7 74.22 77.07
Field consumables 58.4 61.1 58.2 58.73 58.57
Field equipment 9.7 18.1 12.7 11.93 12.37
Field supervision 77.8 77.8 77.8 77.8 77.8
Fuel 16.7 12.8 17.1 16.26 16.51
Lab personnel 20.6 21.5 20.5 20.70 20.64
Lab consumables 43.8 45.8 43.6 44.03 43.90
Lab kit (Amplicor) 479 500.6 477 481.48 480.15
Lab equipment 6.6 6.9 6.5 6.61 6.57
Lab supervision 1.8 1.9 1.8 1.81 1.81
Data entry 1.5 1.5 1.5 1.5 1.50
Estimated total cost/EA 773.9 869.9 795.4 795.07 796.90
Estimated total cost/head of
population
1.176 1.322 1.209 1.21 1.21
doi:10.1371/journal.pntd.0003670.t004
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Examination costs
Over the study area the average EA cost of examining and testing 100 children was $796.90. As
anticipated costs varied by EA geography: and were $773.90, $869.90 and $795.40 in multiple,
single and segment EAs respectively (Table 4). The major laboratory cost was the Amplicor kit
cost, at $480.15 for 100 samples per EA (Fig 3). The major field costs were personnel and su-
pervision (Fig 3), whose relative importance varied depending on the geography of the EA
(data in Table 4). Examining and testing all EAs in the study area, adjusting for EA type, has an
estimated programme cost of $81,283.80 or $ 1.21 per head. Examination alone, without ocular
infection swab sampling or testing has an estimated cost of $24,869.64 over the study area,
$243.82 per EA or $0.37 per head (data from Table 4).
Evaluation of test/treat scenarios
Based on the results of the PRET study, and cost estimates as above we calculated cost estimates
for four alternatives to the base strategy of three rounds of MDA throughout the 102 EAs in
the study area, which are illustrated in Fig 4. We considered two alternatives directly examined
in the PRET study, namely 1) a decision to discontinue MDA in individual EAs based on test-
ing a sample of 100 children within them after the first MDA round, and 2) a decision to dis-
continue MDA over the whole study area based on testing a subsample of EAs for Ct infection.
Further, we examined the costs of decisions 3) to discontinue MDA based on demonstrating a
reduction in TF below 5% after the first MDA round without laboratory testing and 4) to apply
tests for Ct infection before embarking on MDA at all. Finally, we considered the effect of the
cost of azithromycin in alternatives 1)– 4) if the programme had purchased the drug rather
than receiving it from the donation programme.
Sampling calculations
The PRET baseline EA summarised prevalence of Ct infection was 0.8% with a design effect of
4.0, The 6 month post-baseline EA summarised Ct prevalence was 0.1% with a design effect of
Fig 3. Pie charts illustrating relative component costs for treatment, examination and testing.
doi:10.1371/journal.pntd.0003670.g003
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1.9. For an underlying Ct infection prevalence of 0.5–1.0% with these design effects a sample of
at most six EAs would provide 95% confidence that the infection prevalence in the study area
was less than 5%. Conservatively we assume below that 8 EAs would be an adequate sample.
The 6 month post-baseline EA summarised prevalence of TF across all sampled EAs was 2.4%
with a design effect of 4.3. For an assumed underlying TF prevalence of 2–3%, approximately
18 EAs would be required to be sampled to demonstrate that TF was less than 5% with
95% confidence.
Base strategy (census plus 3 MDA rounds-outlined in red in Fig 4)
From the data in Table 2 the estimated cost of census in the study area is $10,639.27 or $0.16
per head. From the data in Table 3 three rounds of standard MDA cost $69,685.38 in the 102
EAs in the study area or $1.05 per head. The total estimated cost of the base strategy applied in
the study area is $80,324.75 or $1.20 per head.
Alternative 1 (discontinue MDA based on testing each EA-outlined in
blue in Fig 4)
From the data in Tables 2,3,and 4 the costs of census plus one standard MDA round plus ex-
amining and testing 100 children in each EA once is $115,151.63 or $1.71 per head. Thus it
costs $34,826.88, $359.50 per EA or $0.51 per head more to test 100 children per EA for Ct
infection than to treat them annually twice. Fig 5 demonstrates how this depends on the kit
cost—in order for testing using an Amplicor-like test to produce savings relative to two un-
necessary MDA rounds, a kit cost of $1.38 or less per result would be required
Fig 4. Illustrating alternative strategies involving MDA and testing in the study area (102 EAs 67,156 people) whose costs are compared. In red is
the base strategy of three rounds of MDA in the study area. In blue is strategy 1, testing all EAs after one round of treatment. In green, strategy 2, testing 8
EAs after one round of treatment. In yellow, strategy 3, discontinuing treatment based on examination after one round of treatment. In purple, strategy 4 of not
starting MDA at all based on prior testing of 8 EAs.
doi:10.1371/journal.pntd.0003670.g004
Relative Costs of MDA and Testing for Trachoma Infection in The Gambia
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003670 April 22, 2015 12 / 18
Alternative 2 (discontinue MDA based on testing a sample of EAs-
outlined in green in Fig 4)
In the PRET study, examination and testing was conducted in 48 EAs at an estimated pro-
gramme cost of $38,163.36 (Table 4). Combining this with census and treatment costs across
the study area from Tables 2 and 3 leads to a cost estimate of $72,004.09 or $1.07 per head. Im-
plementation of the district level stopping rules across the study area based on these 48 EAs
would have resulted in a saving of $8,320.66, or $0.13 a head. However, following the above
sampling calculations, if a sample of 100 children in 8 EAs were examined and tested for Ct in-
fection to show that two further MDA rounds were unnecessary in the study area, this would
cost $40,242.93 or $0.60 per head and save $40,081.82 or $0.60 a head across the study area.
Alternative 3 (discontinue MDA based on examining a sample of EAs-
outlined in orange in Fig 4)
Following the above sampling calculations, we assume that 100 children in each of 18 EAs
could be examined for TF (without testing for Ct infection) to show that two further MDA
rounds were unnecessary in the study area. From the data in Tables 2, 3, and 4 this costs
$38,256.49 or $0.57 a head, and would save $42,068.26 or $0.63 a head across the study area.
Alternative 4 (do not start MDA based on tests for infection-outlined in
purple in Fig 4)
Based on the above sampling calculations we assume that we could demonstrate that three
rounds of MDA were unnecessary through census, sampling and testing in eight of the 102
EAs. From data in Tables 2 and 4 this would cost $7,309.91 or $0.11 per head. Thus, if MDA
Fig 5. Illustrating how the estimated relative costs of testing 100 children in every EA in the study area
(102 EAs, 67,156 people) with an 'Amplicor-like' test after one round of MDA versus continuing MDA in
the study area for three rounds depend on the 'kit costs'(cost of obtaining a result).
doi:10.1371/journal.pntd.0003670.g005
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were not to start at all when baseline infection was less than 5% with 95% confidence, there
would be a saving of $73,014.84, or $1.09 per head.
A head to head comparison of alternatives 1 to 4 is given in S1 Table.
Alternative 5- bought azithromycin
If azithromycin had been bought rather than donated, census followed by three rounds of
MDA in the study area would have cost $461,723.05 or $ 6.91 per head (data in Tables 2 and
3). Census followed by one standard round of MDA would cost $161,031.13 or $2.40 per head.
This is roughly twice the $1.21 cost per head of testing 100 children for infection in every EA.
Discussion
We have shown, in the context of the findings of the PRET study, that tests for infection can be
applied in trachoma control to prevent further redundant MDA rounds and that in circum-
stances where an initial MDA round reduces infection below the decision threshold, this will
save resources. Using programme costs estimated for The Gambia, discontinuing MDA based
on testing 100 children for Ct infection in each of a sample of communities, (drawn from a
total population of 67,156) after one round of MDA, offers cost savings of $0.57 a head relative
to continuing for three MDA rounds, even when the Amplicor test is used. Since PRET found
no difference in effectiveness between these study arms, this is also a cost-effective strategy.
The 3rd WHO Global Scientific Meeting on trachoma [17] made recommendations for tra-
choma surveillance post-MDA based on the sub-district, where a sub-district is a natural or
convenient segmentation of a district of 250,000 people. Here we present calculations extrapo-
lated to the whole PRET study area of 102 census EAs and 67,156 people, which despite being
made up of four Gambian districts, we believe best corresponds to the ‘sub-district’ envisaged
in the recommendations.
We found the average EA treatment cost in The Gambia, based on a single treatment visit
to each community not including census was $227.73, which equates to $0.35 per head of pop-
ulation. Enhancing coverage via an extra treatment visit to each community cost a further
$0.04 per head, improved coverage in 0–9 year-olds by about 3%, but had no effect on out-
come and, in this setting, was not worthwhile. The treatment costs are less than the $ 1.53 per
head reported in South Sudan [18], but similar to the $ 0.25 estimate fromMali [19]. A cost of
$0.50 per person for trachoma treatment has been quoted in the literature when assessing
programme sustainability or cost savings through integrated treatment campaigns targeting
several neglected tropical diseases [18,20,21]. Our results are in line with this estimate. The es-
timated total annual cost of mass treatment with standard coverage and donated azithromycin
for the study area (102 EAs and 67.156 people) was $23,224 per round. The main drivers were
personnel costs followed by supervision. Others have also found personnel to be the major
cost from all cost categories in population-based prevalence surveys [22] and trachoma mass
antibiotic treatment distributions [18]. Interestingly, both these studies found transportation
to be the next most expensive cost category after personnel, whereas it was not a major cost in
our study. This is likely a reflection of the high population density, small distances travelled
and relatively good terrain in The Gambia. Costs will likely be higher in countries where the
population is sparse and the terrain unforgiving, reflecting increased personnel and transpor-
tation costs. This is apparent in the study from the Ayod county of Southern Sudan where a
plane had to be chartered to transport personnel [22]. There are different, but not markedly
different, costs associated with the variations in EA geography, presumably reflecting different
field team organisation, and more hierarchical social structures in smaller settlements, offset
by higher transport costs in visiting multiple settlements.
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The average cost of testing 100 children per EA for Ct infection was $796.90. The major
contribution was the kit cost of Amplicor testing at $480.15 per EA. This is less than the cost of
100 Amplicor tests, but more than the cost of 20, because of the strategy of testing in pools of
five (requiring 20 tests per 100) and then retesting each individual sample within a positive
pool [23], which here reduced costs by over 60% relative to testing each sample individually.
We show that, at the EA level, testing using an ‘Amplicor-like’ test would not cost less than two
further rounds of MDA unless the kit cost for testing the EA was below $138 per EA or $1.38
per result. However because the number of EAs that would need to be tested to establish dis-
trict level prevalence with sufficient precision to guide MDA treatment decisions is, in this
case, relatively small a district level decision process similar to our ‘stopping rule’ has the po-
tential to save money even with the current costs of testing. The Amplicor test used in this
study is no longer commercially available, but alternatives such as the COBAS Amplicor CT/
NG Test, Aptima Combo 2 Assay (Gen-Probe Inc. CA, USA), and the Real-time CT/NG Assay
(Abbott Laboratories, Illinois, USA) platform are no cheaper and some [24] but not all have
had pooling strategies validated. Nevertheless, this study suggests that even the application of
relatively costly Nucleic Acid Amplification Tests (NAATs) may save resources if a sample of
representative communities was tested for infection before MDA was implemented
The ‘stopping rule’ used in PRET was an arbitrary one based on the observation that if no
infections were found in a sample of 100 children then there was 95% confidence that the true
infection prevalence was less than 5%. Whether an infection prevalence of 5% in 0–5 year-olds
is the best cut-off for discontinuing MDA is unknown. It has been pointed out by others that
studies to ascertain a threshold or thresholds below which trachoma infections do not persist
and will then disappear on their own (i.e. the existence of an ‘Allee effect’) will be very difficult
to conduct against the background of worldwide downward secular trends in trachoma preva-
lence [25]. However, one interpretation of the PRET data would be that The Gambia reached
such a point before the PRET study started, when the application of tests for infection would
have shown a baseline infection prevalence of 0.8%, The potential we outline for a testing strat-
egy to save money is likely to vary with both TF prevalence and Ct infection rates and with the
number of children tested in a population unit. Here TF prevalences in the 5–10% range were
compatible with extremely low rates of Ct infection, but the extent to which this is generalisable
needs to be established in other studies in which district or sub-district level TF and Ct infec-
tion rates are both estimated. In PRET, 100 children per EA were tested as if there were zero
cases of infection there was 95% confidence that the true rate in the EA was less than 5%. For a
district rather than EA based MDA decision fewer children per EA could be tested and our
data could be extrapolated to estimate costs in those circumstances. We suggest that tests for
Ct infection will be needed to confirm whether, or, more likely, when a country, region or dis-
trict is ready to discontinue MDA. We show that the application of such tests with appropriate
sampling schemes and decision rules will save money relative to initiating or continuing MDA,
even with the current costs of NAATs.
Our study had a number of limitations which may affect the results. We did not include
the opportunity cost of people coming to be treated and/or examined in relation to what they
would otherwise have been doing, what this represented in monetary terms, and how long
each adult spent with the team. The NEHP workers administering treatment were taken away
from their usual tasks, also incurring societal costs. Our total cost estimates are therefore likely
to under-estimate the total societal cost. By not including the opportunity cost, we may have
masked cost differences between the strategies, depending on the amount of time an adult
spent when attending and accompanying children for treatment distribution, compared with
accompanying children for examination. Studies comparing different trachoma treatment
strategies have noted that patient (opportunity) cost is a major cost in mass azithromycin
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treatment with donated drug [19,26]. We probably under-estimated the cost of the extra treat-
ment day in the enhanced treatment strategy as, per person, the teams would have spent lon-
ger per person treated trying to find the few remaining individuals needing treatment than
treating people when arriving in an EA for the first day. As the extra day had no impact on
outcome, this concern is minor. Finally, however, our data are taken from a research project.
Although we have made substantial efforts to separate out and remove research costs, the cen-
sus, treatment and examination activities may have been organised and conducted differently
if entirely planned and run by the programme. Programmes may elect for example to combine
census and treatment activities. Thus, absolute costs would probably vary with a different
project organisation (and be different in another low prevalence country), but we suggest that
the relative cost differences we highlight between three annual MDAs and a stopping rule
based on testing for infection would be less affected.
If azithromycin were purchased rather than donated, the cost of treatment was 6.7 times
greater with azithromycin constituting over 80% of the total cost. This is much more than the
costs of testing and, without the donation programme it would be cheaper to test first if there
were even a minority of communities with low levels of infection as purchasing azithromycin is
prohibitively expensive [19,26–28] This underlines the importance of the donation to national
eye health programmes in their quest to eliminate trachoma as a public health problem.
Conclusion
We have shown that the strategy of three annual rounds of mass azithromycin treatment of a
sub-district are more expensive than examining and testing ocular swabs from a sample of
EAs, if, as in the PRET study treatment can then be discontinued based on the results after one
round. Therefore, in low prevalence settings, it could be both cost-saving and cost-effective to
implement a stopping rule strategy.
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